Neuropathy News and Research

RSS

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

Amputation prevention tips for diabetic patients

While "One Foot, Two Foot, Red Foot, Blue Foot" may be the opening line of a humorous children's book by Dr. Seuss, foot complications are no laughing matter to the 20 million Americans with diabetes. According to the American Orthopaedic Foot & Ankle Society (AOFAS), ulceration, infection, and gangrene are the most common foot and ankle problems of the diabetic patient.

21 Oct 2009

New cutting edge nerve procedure relieves migraine permanently

The Plastic Surgery Center today announced that a 57-year-old Plainfield man reports he is free of constant headache pain after undergoing a new cutting edge nerve procedure to permanently eliminate pain caused by migraines. The procedure was performed by plastic and reconstructive surgeon Dr. Matthew Kaufman, of the Plastic Surgery Center in New Jersey on August 4, 2009.

21 Oct 2009

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

19 Oct 2009

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Relying on an independent study by the Institute of Medicine (IOM), Secretary of Veterans Affairs Eric K. Shinseki decided to establish a service-connection for Vietnam Veterans with three specific illnesses based on the latest evidence of an association with the herbicides referred to as Agent Orange.

15 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.

14 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Sangamo declares pricing of common stock; grants option to purchase additional 450,000 shares

Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of a public offering of 3,000,000 shares of its common stock. The offering is expected to close on or about October 13, 2009, subject to the satisfaction of customary closing conditions.

8 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

Findings from a study of Vicor's PD2i VS to be presented at the Resuscitation Science Symposium 2009

David H. Fater, CEO of Vicor Technologies, Inc., today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), will present findings from a study of Vicor's PD2i VS™ (Vital Sign) at the American Heart Association's Resuscitation Science Symposium 2009 on November 14-15, 2009 in Orlando, Florida.

7 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Biochemics signs research collaboration agreement with Unilever

BioChemics, Inc. a company “enhancing drug delivery through biophysical modulation,” is pleased to announce the signing of a research collaboration agreement with Unilever, one of the world’s largest consumer goods companies, to utilize BioChemics’ proprietary topical delivery technology for the delivery of Unilever’s compounds.

5 Oct 2009

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

Doris Duke Innovations award for sickle cell disease research

Sangamo BioSciences, Inc. announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation.

1 Oct 2009

Altered state physiology drug development platform to treat an array of human conditions

David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

1 Oct 2009

New drug combination releives neuropathic pain and improves sleep

People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs.

1 Oct 2009

Neuropathy News and Research

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Amputation prevention tips for diabetic patients

New cutting edge nerve procedure relieves migraine permanently

Testicular cancer survivors at risk of effective treatment

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Sangamo declares pricing of common stock; grants option to purchase additional 450,000 shares

Research to explore diagnosis and treatment of rare diseases

Findings from a study of Vicor's PD2i VS to be presented at the Resuscitation Science Symposium 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Biochemics signs research collaboration agreement with Unilever

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Doris Duke Innovations award for sickle cell disease research

Altered state physiology drug development platform to treat an array of human conditions

New drug combination releives neuropathic pain and improves sleep

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News